appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Suven Pharmaceuticals Ltd
SUVENPHAR
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Suven Pharmaceuticals is engaged in Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
L G Balakrishnan & Bros Ltd leads gainers in ‘A’ group
4 weeks ago•Business Standard
Suven Pharma Max Health can rally up to 9 Angel One
1 month ago•Business Standard
Suven Pharma soars after signing deal to acquire oligo drugs maker Sapala Organics
1 month ago•Business Standard
Suven Pharmaceuticals Share Price Rises 6% On CDMO Firm Sapala Organics Acquisition - News18
1 month ago•News18
Suven Pharmaceuticals Gains After Contract Manufacturing Firm Acquisition
1 month ago•Bloomberg Quint
Suven Pharma stock rises 6 on nod to acquire Sapala Organics for Rs 230 cr
1 month ago•Business Standard
Top buzzing stocks June 14 Ambuja Defence Suven Pharma Zaggle Nalco
1 month ago•Business Standard
Suven Pharma To Acquire 67.5% Stake In Sapala Organics For Rs 229.5 Crore
1 month ago•Bloomberg Quint
Suven Pharma to acquire 67.5% stake in Sapala Organics for Rs 229.5 cr
1 month ago•Business Standard
Recent EventsAll events
Notice Of Shareholders Meetings-XBRL
SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 09-Aug-2024 | Download
SUVEN PHARMACEUTICALS LIMITED has informed the Exchange about Notice of Shareholders Meeting for Annual General Meeting to be held on 09-Aug-2024 | Download
Cash Dividend
Special • Div/Share: ₹ 5
Decreased Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 9.90%